Evidence map›Paper›PMID 36872783›Full record

ReviewJournal of Alzheimer's disease : JAD2023

Neuropsychiatric Symptoms and Commonly Used Biomarkers of Alzheimer's Disease: A Literature Review from a Machine Learning Perspective.

Jay Shah, Md Mahfuzur Rahman Siddiquee, Janina Krell-Roesch, Jeremy A Syrjanen, Walter K Kremers, Maria Vassilaki, Erica Forzani, Teresa Wu, Yonas E Geda

Abstract readReview
In one paragraph

Review in Journal of Alzheimer's disease : JAD, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Review
  4. Review
  5. Article
  6. Review
  7. Article
  8. Review
  9. Review
  10. Article
  11. Review
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Jay ShahSchool of Computing and Augmented Intelligence, Arizona State University, Tempe, AZ, USA.
Md Mahfuzur Rahman SiddiqueeSchool of Computing and Augmented Intelligence, Arizona State University, Tempe, AZ, USA.
Janina Krell-RoeschDepartment of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, USA.
Jeremy A SyrjanenDepartment of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, USA.
Walter K KremersDepartment of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, USA.
Maria VassilakiDepartment of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, USA.
Erica ForzaniBiodesign Institute, Arizona State University, Tempe, AZ, USA.
Teresa WuSchool of Computing and Augmented Intelligence, Arizona State University, Tempe, AZ, USA.
Yonas E GedaDepartment of Neurology and the Franke Global Neuroscience Education Center, Barrow Neurological Institute, Phoenix, AZ, USA.

Funding

Pathways linking neuropsychiatric symptoms with Alzheimer's disease neuroimaging biomarkers and the outcome of incident Mild Cognitive Impairment/ DementiaR01AG057708 · NIA · ST. JOSEPH'S HOSPITAL AND MEDICAL CENTER · PI GEDA, YONAS E · 2018 to 2022
$1.7M
NIA NIH HHS R01 AG057708
6 · The paper itself

Abstract

There is a growing interest in the application of machine learning (ML) in Alzheimer's disease (AD) research. However, neuropsychiatric symptoms (NPS), frequent in subjects with AD, mild cognitive impairment (MCI), and other related dementias have not been analyzed sufficiently using ML methods. To portray the landscape and potential of ML research in AD and NPS studies, we present a comprehensive literature review of existing ML approaches and commonly studied AD biomarkers. We conducted PubMed searches with keywords related to NPS, AD biomarkers, machine learning, and cognition. We included a total of 38 articles in this review after excluding some irrelevant studies from the search results and including 6 articles based on a snowball search from the bibliography of the relevant studies. We found a limited number of studies focused on NPS with or without AD biomarkers. In contrast, multiple statistical machine learning and deep learning methods have been used to build predictive diagnostic models using commonly known AD biomarkers. These mainly included multiple imaging biomarkers, cognitive scores, and various omics biomarkers. Deep learning approaches that combine these biomarkers or multi-modality datasets typically outperform single-modality datasets. We conclude ML may be leveraged to untangle the complex relationships of NPS and AD biomarkers with cognition. This may potentially help to predict the progression of MCI or dementia and develop more targeted early intervention approaches based on NPS.

Indexed as

Alzheimer DiseaseCognitive DysfunctionBiomarkersCognitionDisease ProgressionHumansMachine LearningBiomarkersAlzheimer’s diseasecognitiondeep learningmachine learningneuropsychiatric symptoms

Identifiers

PMID36872783
PMCPMC11102734

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.